Is LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Recent Stock Performance Tethered To Its Strong Fundamentals?
Is LBX Pharmacy Chain Joint Stock Company's (SHSE:603883) Recent Stock Performance Tethered To Its Strong Fundamentals?
LBX Pharmacy Chain (SHSE:603883) has had a great run on the share market with its stock up by a significant 11% over the last month. Given that the market rewards strong financials in the long-term, we wonder if that is the case in this instance. In this article, we decided to focus on LBX Pharmacy Chain's ROE.
LBX Pharmacy Chain公司(SHSE: 603883)在股市上表現良好,其股票比上個月大幅上漲了11%。鑑於從長遠來看,市場會獎勵強勁的財務狀況,我們想知道在這種情況下是否如此。在本文中,我們決定重點關注LBX藥房連鎖店的投資回報率。
ROE or return on equity is a useful tool to assess how effectively a company can generate returns on the investment it received from its shareholders. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
投資回報率或股本回報率是評估公司如何有效地從股東那裏獲得投資回報的有用工具。簡而言之,投資回報率顯示了每美元從其股東投資中產生的利潤。
How Is ROE Calculated?
ROE 是如何計算的?
The formula for ROE is:
ROE 的公式是:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity
股本回報率 = 淨利潤(來自持續經營業務)÷ 股東權益
So, based on the above formula, the ROE for LBX Pharmacy Chain is:
因此,根據上述公式,LBX 藥房連鎖店的投資回報率爲:
15% = CN¥1.1b ÷ CN¥7.3b (Based on the trailing twelve months to September 2023).
15% = 人民幣1.1億元/人民幣7.3億元人民幣(基於截至2023年9月的過去十二個月)。
The 'return' refers to a company's earnings over the last year. Another way to think of that is that for every CN¥1 worth of equity, the company was able to earn CN¥0.15 in profit.
“回報” 是指公司去年的收益。另一種看法是,每持有價值1元人民幣的股權,公司就能獲得0.15元人民幣的利潤。
What Has ROE Got To Do With Earnings Growth?
投資回報率與收益增長有什麼關係?
We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.
我們已經確定,投資回報率是衡量公司未來收益的有效盈利指標。根據公司選擇將多少利潤進行再投資或 “保留”,我們便能夠評估公司未來創造利潤的能力。假設其他一切保持不變,那麼與不一定具有這些特徵的公司相比,投資回報率和利潤保留率越高,公司的增長率就越高。
LBX Pharmacy Chain's Earnings Growth And 15% ROE
LBX 連鎖藥店的收益增長和 15% 的投資回報率
To begin with, LBX Pharmacy Chain seems to have a respectable ROE. Especially when compared to the industry average of 8.4% the company's ROE looks pretty impressive. Probably as a result of this, LBX Pharmacy Chain was able to see a decent growth of 14% over the last five years.
首先,LBX連鎖藥房似乎具有可觀的投資回報率。特別是與行業平均水平的8.4%相比,該公司的投資回報率看起來相當可觀。可能是由於這個原因,LBX藥房連鎖店在過去五年中得以實現14%的可觀增長。
Next, on comparing LBX Pharmacy Chain's net income growth with the industry, we found that the company's reported growth is similar to the industry average growth rate of 13% over the last few years.
接下來,在將LBX Pharmacy Chain的淨收入增長與該行業的淨收入增長進行比較時,我們發現該公司報告的增長與過去幾年13%的行業平均增長率相似。
The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. Is LBX Pharmacy Chain fairly valued compared to other companies? These 3 valuation measures might help you decide.
爲公司附加價值的基礎在很大程度上與其收益增長息息相關。對於投資者來說,重要的是要知道市場是否對公司的預期收益增長(或下降)進行了定價。這樣做將幫助他們確定股票的未來是樂觀還是不祥的。與其他公司相比,LBX藥房連鎖店的估值是否合理?這3種估值指標可能會幫助您做出決定。
Is LBX Pharmacy Chain Using Its Retained Earnings Effectively?
LBX連鎖藥房是否有效地使用了其留存收益?
LBX Pharmacy Chain has a three-year median payout ratio of 30%, which implies that it retains the remaining 70% of its profits. This suggests that its dividend is well covered, and given the decent growth seen by the company, it looks like management is reinvesting its earnings efficiently.
LBX Pharmacy Chain的三年派息率中位數爲30%,這意味着它保留了剩餘的70%的利潤。這表明其股息覆蓋範圍良好,鑑於該公司的可觀增長,管理層似乎正在有效地對其收益進行再投資。
Besides, LBX Pharmacy Chain has been paying dividends over a period of eight years. This shows that the company is committed to sharing profits with its shareholders. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 32%. As a result, LBX Pharmacy Chain's ROE is not expected to change by much either, which we inferred from the analyst estimate of 15% for future ROE.
此外,LBX藥房連鎖店已經在八年內派發了股息。這表明該公司致力於與股東分享利潤。我們的最新分析師數據顯示,公司未來三年的派息率預計約爲32%。因此,預計LBX藥房連鎖店的投資回報率也不會有太大變化,我們從分析師對未來投資回報率爲15%的估計中推斷了這一點。
Conclusion
結論
On the whole, we feel that LBX Pharmacy Chain's performance has been quite good. In particular, it's great to see that the company is investing heavily into its business and along with a high rate of return, that has resulted in a sizeable growth in its earnings. That being so, the latest analyst forecasts show that the company will continue to see an expansion in its earnings. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
總的來說,我們認爲LBX藥房連鎖店的表現相當不錯。特別是,很高興看到該公司正在對其業務進行大量投資,再加上高回報率,這爲其收益帶來了可觀的增長。既然如此,分析師的最新預測顯示,該公司的收益將繼續增長。要了解有關公司未來收益增長預測的更多信息,請查看這份免費的分析師預測報告,以了解更多信息。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。